Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting

Background Metabolomics is the rapidly evolving field of the comprehensive measurement of ideally all endogenous metabolites in a biological fluid. However, no single analytic technique covers the entire spectrum of the human metabolome. Here we present results from a multiplatform study, in which we investigate what kind of results can presently be obtained in the field of diabetes research when combining metabolomics data collected on a complementary set of analytical platforms in the framework of an epidemiological study. Methodology/Principal Findings 40 individuals with self-reported diabetes and 60 controls (male, over 54 years) were randomly selected from the participants of the population-based KORA (Cooperative Health Research in the Region of Augsburg) study, representing an extensively phenotyped sample of the general German population. Concentrations of over 420 unique small molecules were determined in overnight-fasting blood using three different techniques, covering nuclear magnetic resonance and tandem mass spectrometry. Known biomarkers of diabetes could be replicated by this multiple metabolomic platform approach, including sugar metabolites (1,5-anhydroglucoitol), ketone bodies (3-hydroxybutyrate), and branched chain amino acids. In some cases, diabetes-related medication can be detected (pioglitazone, salicylic acid). Conclusions/Significance Our study depicts the promising potential of metabolomics in diabetes research by identification of a series of known and also novel, deregulated metabolites that associate with diabetes. Key observations include perturbations of metabolic pathways linked to kidney dysfunction (3-indoxyl sulfate), lipid metabolism (glycerophospholipids, free fatty acids), and interaction with the gut microflora (bile acids). Our study suggests that metabolic markers hold the potential to detect diabetes-related complications already under sub-clinical conditions in the general population.

[1]  Aldons J. Lusis,et al.  A thematic review series: systems biology approaches to metabolic and cardiovascular disorders , 2006, Journal of Lipid Research.

[2]  Hans-Werner Mewes,et al.  Bioinformatics analysis of targeted metabolomics--uncovering old and new tales of diabetic mice under medication. , 2008, Endocrinology.

[3]  Christian Gieger,et al.  Metabolic Profiling Reveals Distinct Variations Linked to Nicotine Consumption in Humans — First Results from the KORA Study , 2008, PloS one.

[4]  C. Berne,et al.  Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. , 1999, Kidney international.

[5]  T. Niwa,et al.  Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. , 1994, The Journal of laboratory and clinical medicine.

[6]  M. Ward,et al.  Crystal Growth Inhibitors for the Prevention of l-Cystine Kidney Stones Through Molecular Design , 2010, Science.

[7]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[8]  A. Watson,et al.  Thematic Review Lipidomics: a Global Approach to Lipid Analysis in Biological Systems , 2022 .

[9]  Bernhard Liebl,et al.  Advances in analytical mass spectrometry to improve screening for inherited metabolic diseases , 2003, European Journal of Pediatrics.

[10]  C. Gieger,et al.  SLC2A9 influences uric acid concentrations with pronounced sex-specific effects , 2008, Nature Genetics.

[11]  A. Smilde,et al.  Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. , 2006, Analytical chemistry.

[12]  R. DeFronzo,et al.  Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. , 1988, Diabetes/metabolism reviews.

[13]  A. Mooradian.  Dyslipidemia in type 2 diabetes mellitus , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[14]  Christian Gieger,et al.  A genome-wide perspective of genetic variation in human metabolism , 2010, Nature Genetics.

[15]  C. Gieger,et al.  KORA-gen - Resource for Population Genetics, Controls and a Broad Spectrum of Disease Phenotypes , 2005 .

[16]  G. Eknoyan,et al.  Plasma acid-base patterns in diabetic ketoacidosis. , 1982, The New England journal of medicine.

[17]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[18]  N. Ruderman.  Muscle amino acid metabolism and gluconeogenesis. , 1975, Annual review of medicine.

[19]  Dominique Gauguier,et al.  Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models , 2007, Nature Genetics.

[20]  Johan Trygg,et al.  Chemometrics in metabolomics--a review in human disease diagnosis. , 2010, Analytica chimica acta.

[21]  O. Fiehn.  Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[22]  J. McGill,et al.  Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. , 2003, Diabetes technology & therapeutics.

[23]  J. Chiasson,et al.  Ketoacidosis and the hyperosmolar hyperglycemic state in adult diabetic patients. Diagnosis and treatment. , 2003, Minerva medica.

[24]  D. Layman.  The role of leucine in weight loss diets and glucose homeostasis. , 2003, The Journal of nutrition.

[25]  L. Borghi,et al.  Plasma and Skeletal Muscle Free Amino Acids in Type I, Insulin-treated Diabetic Subjects , 1985, Diabetes.

[26]  Glanville Nt,et al.  The effect of insulin deficiency, dietary protein intake, and plasma amino acid concentrations on brain amino acid levels in rats. , 1985 .

[27]  Daniel Raftery,et al.  Quantitative Metabolomics by 1H-NMR and LC-MS/MS Confirms Altered Metabolic Pathways in Diabetes , 2010, PloS one.

[28]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Niwa,et al.  Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. , 1996, Seminars in nephrology.

[30]  N. Glanville,et al.  The effect of insulin deficiency, dietary protein intake, and plasma amino acid concentrations on brain amino acid levels in rats. , 1985, Canadian journal of physiology and pharmacology.

[31]  P. Elliott,et al.  Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. , 2006, Analytical chemistry.

[32]  Xin Lu,et al.  Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. , 2009, Analytica chimica acta.

[33]  Julian L Griffin,et al.  Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. , 2006, Pharmacogenomics.

[34]  Jeremiah Stamler,et al.  Detection of urinary drug metabolite (xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy. , 2007, Analytical chemistry.

[35]  Andrea Natali,et al.  α-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population , 2010, PloS one.

[36]  J. Griffin.  The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[37]  Janet B McGill,et al.  Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. , 2004, Diabetes care.

[38]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[39]  A. Saghatelian,et al.  Exploring disease through metabolomics. , 2010, ACS chemical biology.

[40]  Ian J. Brown,et al.  Human metabolic phenotype diversity and its association with diet and blood pressure , 2008, Nature.

[41]  J. Pongratz,et al.  Validation of MCADD newborn screening , 2009 .

[42]  Ivano Bertini,et al.  Evidence of different metabolic phenotypes in humans , 2008, Proceedings of the National Academy of Sciences.

[43]  W. Thompson,et al.  Fibrinogen/fibrin in atherogenesis , 1992, European Journal of Epidemiology.

[44]  M. Wenk.  The emerging field of lipidomics , 2005, Nature Reviews Drug Discovery.

[45]  J. Jankowski,et al.  Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. , 2003, The Journal of clinical investigation.

[46]  M. Milburn,et al.  Analysis of the adult human plasma metabolome. , 2008, Pharmacogenomics.

[47]  W. Fujimoto.  The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 2000, The American journal of medicine.

[48]  Christian Gieger,et al.  Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum , 2008, PLoS genetics.

[49]  E. B. Smith.  Fibrinogen, fibrin and the arterial wall. , 1995, European heart journal.

[50]  Elaine Holmes,et al.  Metabonomics in pharmaceutical R & D , 2007, The FEBS journal.

[51]  D. Layman,et al.  Potential importance of leucine in treatment of obesity and the metabolic syndrome. , 2006, The Journal of nutrition.

[52]  Erin E. Carlson,et al.  Targeted profiling: quantitative analysis of 1H NMR metabolomics data. , 2006, Analytical chemistry.

[53]  Gabi Kastenmüller,et al.  Variation in the human lipidome associated with coffee consumption as revealed by quantitative targeted metabolomics. , 2009, Molecular nutrition & food research.

[54]  Patrice D Cani,et al.  The role of the gut microbiota in energy metabolism and metabolic disease. , 2009, Current pharmaceutical design.

[55]  A. Grubb,et al.  The Increase of Plasma Homocysteine Concentrations with Age Is Partly due to the Deterioration of Renal Function as Determined by Plasma Cystatin C , 1998, Clinical chemistry and laboratory medicine.

[56]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[57]  A. B. Robinson,et al.  Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[58]  G. Marchesini,et al.  Branched-chain amino acids and alanine as indices of the metabolic control in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients , 1982, Diabetologia.